International journal of laboratory hematology最新文献

{"title":"T-Cell Prolymphocytic Leukemia With PDGFRB Rearrangement in the Setting of Neurofibromatosis Type 1.","authors":"Yue Zhao, Philip Petersen, Imran Siddiqi, Endi Wang","doi":"10.1111/ijlh.14427","DOIUrl":"https://doi.org/10.1111/ijlh.14427","url":null,"abstract":"","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Anticoagulants on Platelet Counts: A Study and Recommendations From the French Speaking Cellular Hematology Group (GFHC).","authors":"Soraya Wuilleme, Sandrine Girard, Michel Soulard, Bernard Chatelain, Elodie Etienne, Eric Guiheneuf, Franck Geneviève, Aurélie Vedrenne, Jean François Lesesve, Véronique Baccini, Valérie Bardet","doi":"10.1111/ijlh.14430","DOIUrl":"https://doi.org/10.1111/ijlh.14430","url":null,"abstract":"<p><strong>Introduction: </strong>For complete blood count, ethylenediaminetetraacetic acid (EDTA) is universally used and has been recognized as the most robust anticoagulant. However, it may lead to pseudothrombocytopenia (PTCT), due to the formation of platelet clumps, which is currently followed by resampling on sodium citrate. Other possible anticoagulants are citrate theophylline adenosine dipyridamole (CTAD) and MgSO₄. These anticoagulants were compared here for resolution of PTCT and platelet count values and stability.</p><p><strong>Methods: </strong>Paired blood samples were used to compare the four anticoagulants. First, samples containing clumps on EDTA were compared to samples collected on sodium citrate (335), CTAD (31), or MgSO₄ (160). For platelet counts, compared series were of respectively, 168, 191, and 87, paired to PTCT-free EDTA samples. Finally, platelet count stability was evaluated over 2-24 h.</p><p><strong>Results: </strong>MgSO₄, followed by CTAD, was the most efficient to avoid platelet clump formation, while sodium citrate performed poorly. Regarding platelet count, significantly lower values were obtained with sodium citrate (p < 0.0001), with more samples (35% vs. 6.5%) below the 150 × 10⁹/L threshold. Conversely, CTAD yielded similar values as EDTA, while higher counts were observed with MgSO₄ (p = 0.008). Finally, platelet count stability began to decrease at 4 h for sodium citrate, while the other anticoagulants were stable for at least 8 h, up to 12 h for MgSO4 and 24 h for EDTA.</p><p><strong>Conclusions: </strong>This real-life study confirms that sodium citrate should no longer be used to improve platelet counts in patients with platelet clumps, CTAD, if available, and MgSO₄ being much better alternatives.</p>","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Efficient Acute Lymphoblastic Leukemia Screen Framework Based on Multi-Modal Deep Neural Network.","authors":"Qiuming Wang, Tao Huang, Xiaojuan Luo, Xiaoling Luo, Xuechen Li, Ke Cao, Defa Li, Linlin Shen","doi":"10.1111/ijlh.14424","DOIUrl":"https://doi.org/10.1111/ijlh.14424","url":null,"abstract":"<p><strong>Background: </strong>Acute lymphoblastic leukemia (ALL) is a leading cause of death among pediatric malignancies. Early diagnosis of ALL is crucial for minimizing misdiagnosis, improving survival rates, and ensuring the implementation of precise treatment plans for patients.</p><p><strong>Methods: </strong>In this study, we propose a multi-modal deep neural network-based framework for early and efficient screening of ALL. Both white blood cell (WBC) scattergrams and complete blood count (CBC) are employed for ALL detection. The dataset comprises medical data from 233 patients with ALL, 283 patients with infectious mononucleosis (IM), and 183 healthy controls (HCs).</p><p><strong>Results: </strong>The combination of CBC data with WBC scattergrams achieved an accuracy of 98.43% in fivefold cross-validation and a sensitivity of 96.67% in external validation, demonstrating the efficacy of our method. Additionally, the area under the curve (AUC) of this model surpasses 0.99, outperforming well-trained medical technicians.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this framework is the first to incorporate WBC scattergrams with CBC data for ALL screening, proving to be an efficient method with enhanced sensitivity and specificity. Integrating this framework into the screening procedure shows promise for improving the early diagnosis of ALL and reducing the burden on medical technicians. The code and dataset are available at https://github.com/cvi-szu/ALL-Screening.</p>","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Anti-Interfering Platelet Counting Technology Utilizing Conventional Impedance and White Blood Cell Differential Channel.","authors":"Yi Ye, Qi Cai, Gengwen Chen, Zongjun Liu, Yan Liu, Xiaosen Bian, Donglan Yao, Keqian Xu","doi":"10.1111/ijlh.14420","DOIUrl":"https://doi.org/10.1111/ijlh.14420","url":null,"abstract":"<p><strong>Introduction: </strong>Accurate platelet (PLT) counting is crucial for disease diagnosis and treatment, especially under the condition of thrombocytopenia and platelet transfusion. A few PLT counting approaches have been established including impedance and fluorescent methods. The impedance PLT counting (PLT-I) approach could be interfered by small non-PLT particles in the blood, such as RBC/WBC fragments, microcytes, bacteria, and cryoglobulins. The fluorescent PLT counting methods provide a more accurate but rather costly option. Thus, it is highly desirable to develop a new economic-friendly approach with accurate platelet count. In this study, we introduced a novel hybrid PLT counting (PLT-H) strategy to combine the count of smaller-sized PLTs from impedance channel and larger-sized PLTs from conventional white blood cell (WBC) channel to realize a low-cost PLT count with high accuracy.</p><p><strong>Methods: </strong>Blood samples with different PLT levels and no significant interfering factors (confirmed by blood smear) were collected. The PLTs were counted with BC-6800Plus (PLT-I) and compared with the PLT counts from the CD41/CD61 immunoplatelet (immunoPLT) reference method using Beckman Coulter FC-500 flow cytometer. In addition, the morphology and internal structure of PLT treated with hemolytic agents of conventional WBC channel was observed with phase contrast microscopy and electron microscopy. Then the counting accuracy of PLT-H was assessed by comparing PLT count results between BC-720 (PLT-H) and the CD41/CD61 immunoPLT reference method.</p><p><strong>Results: </strong>By comparing PLT-I with immunoPLT, it was found that the impedance PLT counting result will not be interfered by small non-PLT particles when the size of PLT smaller than 10 fL. For large PLT (> 10 fL), PLT count in conventional WBC channel shows good correlations with immunoPLT. Furthermore, after treated with hemolytic agents the PLT still preserves an intact cellular structure and swells slightly, while RBCs are lysis and disappeared upon hemolytic treatment. Lastly, the novel PLT-H result exhibits a good correlation with immunoPLT with a high correlation factor (r = 0.9911).</p><p><strong>Conclusions: </strong>The new PLT counting method PLT-H achieves high accuracy in blood samples with low-cost, and it provide a novel strategy of combining traditional methods for high accurate counting in hematology laboratories.</p>","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare ZMYND8::PDGFRβ Fusion Transcript in Acute Lymphoblastic Leukemia.","authors":"Ailing Deng, Man Wang, Dongyun Jiang, Jiannong Cen, Mengxing Xue, Yun Wang, Xueqing Dou, Qian Wu, Xiaofei Yang, Suning Chen","doi":"10.1111/ijlh.14415","DOIUrl":"https://doi.org/10.1111/ijlh.14415","url":null,"abstract":"","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disseminated Intravascular Coagulation in Pediatric Acute Leukemia: Prevalence, Laboratory Features, and Prognostic Significance of ISTH Score.","authors":"Haya F Al-Khalaila, Manal A Abbas, Muna A Almaharma","doi":"10.1111/ijlh.14425","DOIUrl":"https://doi.org/10.1111/ijlh.14425","url":null,"abstract":"<p><strong>Introduction: </strong>Disseminated intravascular coagulation (DIC) is associated with acute leukemia. DIC prevalence and clinical consequences are complex and varies across acute leukemia subtypes. The International Society of Thrombosis and Hemostasis (ISTH) scoring system is used for the detection of overt DIC.</p><p><strong>Methods: </strong>Children of both sexes (1 day-18 years) with acute leukemia, suspected to have DIC and referred to hematology laboratory were included in the study. DIC score was calculated according to ISTH guidelines from laboratory values obtained within 24 h of admission and repeated after 2 weeks. The DIC cases were classified into overt DIC if ISTH score ≤ 5 and non-overt if ISTH score > 5.</p><p><strong>Results: </strong>Sixty-two children diagnosed with acute leukemia and having the clinical and laboratory diagnostic features of DIC along with 48 age-matched healthy controls participated in the study. DIC was more frequently diagnosed in cases of AML (66.13%) compared to ALL (33.87%). Cases with T-ALL had DIC (19.4%) more frequently than B-ALL type (14.5%). Similarly, children with M5, M2, and M3 had DIC more frequently (16.1%, 15.58% and 14.28%, respectively) compared to other AML types. Overt DIC was observed in 71% of DIC cases with acute leukemia while non-overt DIC was diagnosed in 29% of them. Follow-up for 14 days of non-overt cases showed that 12 out of 18 patients progressed from non-overt to overt DIC with a significant increase in D-dimer and a decline in platelets count. The incidence of bleeding (35.4%) was higher than thrombosis (19.4%) among acute leukemia patients with DIC. An ISTH score ≤ 5 predicted increased intensive care unit (ICU) admission, death and end organ dysfunction with odds ratio of 4.28, 6.77, and 6.67, respectively. Based on receiver-operator analysis of DIC cases classified as overt and non-overt DIC based on ISTH score, D-Dimer was excellent predictor of overt DIC with the high sensitivity and specificity.</p><p><strong>Conclusion: </strong>ISTH score predicts death, ICU admission and organ dysfunction in children with acute leukemia. D-Dimer is an excellent predictor of overt DIC in acute leukemia.</p>","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryptic KMT2A::MLLT10 Rearrangement in a Highly Aggressive Acute Myeloid Leukemia.","authors":"Gerasimos Tsilimidos, Ilaria Scarpelli, Françoise Solly, Marine Gossin, Amandine Segot, Jacqueline Pouw Schoumans, Sabine Blum","doi":"10.1111/ijlh.14423","DOIUrl":"https://doi.org/10.1111/ijlh.14423","url":null,"abstract":"","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Characterization of δβ Thalassemia/Hereditary Persistence of Fetal Hemoglobin and Its Correlation With Clinical and Hematological Profile; a Single Center Study in North India.","authors":"R Gupta, A Shah, K Gupta, D Chandra, A Sharma, K Rahman, M K Singh, S Yadav, R Kashyap","doi":"10.1111/ijlh.14419","DOIUrl":"https://doi.org/10.1111/ijlh.14419","url":null,"abstract":"<p><strong>Background: </strong>δβ-thalassemia/HPFH is an uncommon hemoglobinopathy characterized by decreased or the total absence of production of δ- and β-globin and increased HbF levels. Both these disorders have variable genotype and phenotype, but significant overlap in the clinical and laboratory findings. Given the lack of literature in this regard, the study aimed to estimate the prevalence of the disease and evaluate its clinical, hematological, and molecular profile in India.</p><p><strong>Material and methods: </strong>This was a retrospective study where all samples with HbF level ≥ 5% and suspected to be δβ-thalassemia/HPFH, based on the HPLC, were included in the study over 3.5 years. The demographic and clinical details were retrieved from the electronic medical records. Gap-PCR was carried out to characterize the molecular defect for the HbF determinant, while amplification refractory mutation system (ARMS-PCR) was carried out for β-thalassemia genoyping. Clinical and laboratory parameters of heterozygous and homozygous/compound heterozygous δβ thalassemia deletions were compared.</p><p><strong>Results: </strong>A total of 65 individuals (0.8%) were diagnosed with δβ-thalassemia/HPFH; these included 45 (69%) patients in the heterozygous group and 20 (31%) cases in the homozygous/compound heterozygous subgroup. While all the carrier states were asymptomatic, 80% of the patients in the homozygous/compound heterozygous state were symptomatic with a thalassemia intermedia-like profile. The median Hb levels were 12.3 g/dL (range -9.5-18.2) and 8.0 g/dL (range 3.8-15.1) respectively. Molecular profiling identified heterozygous Asian Indian inversion deletion ^Gγ(^Aγδβ)⁰ mutation in 50% of cases, heterozygous HPFH-3 (Indian HPFH, 48.5 kb deletion) in 14% cases, and homozygous ^Gγ(^Aγδβ)⁰-thalassemia in 21% cases. Compound heterozygous HPFH-3/^Gγ(^Aγδβ)⁰ mutation with β-thalassemia was observed in 8.9% and 3.5%, respectively. In one case, the HbF determinant could not be identified. Heterozygous (HBB:c. 92+5G>C), was the most frequent co-inherited β-thalassemia mutation in the compound heterozygous patients.</p><p><strong>Conclusion: </strong>The study highlights that high HbF determinants, like δβ thalassemia and HPFH, are relatively more frequent in the Indian subcontinent, and their co-inheritance with β-thalassemia results in a moderately severe disease. Accurate identification of molecular defects is important for prenatal diagnosis and genetic counseling.</p>","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zopiclone Overdose Is an Important and Under-Recognized Cause of Drug-Induced Oxidative Hemolysis: A Case Series Identified by Heinz Body Test Request.","authors":"Wing Kit Lam, Winnie Yim Fong Law, Sze Fai Yip","doi":"10.1111/ijlh.14421","DOIUrl":"https://doi.org/10.1111/ijlh.14421","url":null,"abstract":"","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Applications of Bone Marrow CD34 Immunohistochemistry (BM CD34 IHC) Assay: International Council for Standardization in Hematology (ICSH) Guidelines.","authors":"Emina Emilia Torlakovic, Katherine R Calvo, Tracy George, Elizabeth Hyjek, Szu-Hee Lee, Anna Porwit, Elena Sabattini, Leonie Saft, Xiaoge Zhou, Alexandar Tzankov","doi":"10.1111/ijlh.14411","DOIUrl":"https://doi.org/10.1111/ijlh.14411","url":null,"abstract":"<p><strong>Introduction: </strong>Investigation of bone marrow (BM) trephine biopsies and/or clot sections by CD34 immunohistochemistry (IHC) testing has been used by pathologists for several decades, and its clinical value has been well established with QBEND10 being the most frequently used primary antibody (Ab) clone. However, most other parameters related to the IHC protocol as well as the readout vary widely between clinical laboratories and in the published literature. The ICSH Working Group having reviewed the published evidence has established guidelines that will help to harmonize performance and reporting of CD34 IHC on BM biopsies.</p><p><strong>Methods: </strong>The methodology is based on the published \"guidelines for guidelines\" (GRADE, AGREE) with modifications to the specific laboratory medicine environment and to specific key questions. Review of the published literature resulted in 49 articles relevant to clinical applications of the BM CD34 IHC. Five key questions were addressed including testing indications, technical performance, readout methodology, terminology, and reporting.</p><p><strong>Results: </strong>A total of 23 guidelines were grouped according to the key questions.</p><p><strong>Conclusion: </strong>BM CD34 IHC testing is complex with both the protocol and the pathologist's readout requiring validation to ensure reported results are reproducible and accurate. The readout/interpretation must be adapted to a specific purpose of the assay (clinicopathological question) and the type and overall sample quality. Standardized terminology and reporting are essential if CD34 IHC assay is being used for clinical diagnostics.</p>","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}